Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing i
5 Midcap Magic Formula Stocks For Total Return
01:12pm, Sunday, 16'th Aug 2020
Introduction To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me. This week I did a complete re-read of Jo
ROCE Insights For Catalyst Pharmaceuticals
02:30pm, Friday, 14'th Aug 2020
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 million. Despite the increase in sales this
Why Catalyst Pharmaceuticals Stock Is Crashing Today
01:27pm, Tuesday, 11'th Aug 2020
Shares of the rare-disease drugmaker Catalyst Pharmaceuticals (NASDAQ: CPRX) are under pressure Tuesday morning. Catalyst's stock is sinking in response to the news that the company's effort to expan
-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutatio
Griffon Corporation Announces Proposed Offering of Common Stock
12:00am, Tuesday, 11'th Aug 2020
Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) announced today that it intends to offer and sell, subject to market and other conditions,
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
09:55pm, Monday, 10'th Aug 2020
Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
08:15pm, Monday, 10'th Aug 2020
\- Firdapse® Second Quarter Net Revenues of $29.6 Million \- Health Canada Approves Marketing Authorization for Firdapse® for Treating LEMS Patients\- MuSK-MG Phase 3 Trial did not Achieve Statisti
It’s a Terrible Idea to Retire With ONLY Your OAS and CPP Pension
07:00pm, Monday, 10'th Aug 2020
Countless retirees are regretting not building enough of a nest egg after discovering that the OAS and CPP are insufficient. The Toronto-Dominion Bank stock, which could provide lifetime income, can b
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
5 Midcap Magic Formula Stocks For Total Return
10:34pm, Friday, 07'th Aug 2020
Considering all that has happened in 2020, I thought it might be interesting to present a screen of stocks based on Joel Greenblatt’s magic formula.
Lucinda wonders how to organize investments after the coronavirus accelerated her decision to sell her house
10:00pm, Friday, 07'th Aug 2020
Her existing portfolio is a mixture of ETFs and mutual funds with an asset mix of 48-per-cent stocks and 52-per-cent cash and fixed income
Earnings Preview: Catalyst Pharmaceuticals
03:11pm, Friday, 07'th Aug 2020
Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters guide for this Monday's Q2 earnings announcement.Earning
Retirees: Boost Your CPP Payments the Easy Way
12:33pm, Thursday, 06'th Aug 2020
Here's how retirees can support CPP payouts by investing in quality dividend companies such as Pembina Pipeline (TSX:PPL).
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS
12:03pm, Thursday, 06'th Aug 2020
CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing i
